I agree. With the RBL study ending in August we should

I agree. With the RBL study ending in August we should have a lot of news to be released in the next few weeks. I suspect Leo knows most of the RBL results.I would expect he will release some next week

sometime in the next few weeks we could hear:

-SI for Brilacidin
-Comparison SI level for Brilacidin and Remdesivir
-Study of Brilacidin and Remdesivir combination for possible synergy
-Toxicity studies for Remdesivir and Brilacidin
-More dosage information for Brilacidin
-Confirmation of Brilacidin's anti inflammatory effects and mechanisms of the immunomodulation {from PHRI}
-Preprint peer review studies
-End of in vitro trial of Brilacidin summary with data
-Details of Mechanism of Action including virucidal, anti attachment and anti replication
-Plans for human clinical trials
-Increased staffing at IPIX for clinical trials or CRO
-Clinical trial location
-Confirmation of IV Brilacidin ready for clinical trials
-CDMO report
-Human clinical trial design
-Future studies for other viruses eg Encephalitis, SARS, MERS and others as a broad spectrum antiviral
-Additional RBL studies
-Funding

and I am sure a few surprises

It is an exciting time to be invested in IPIX

Good luck to all, Farrell